Format

Send to

Choose Destination
Curr Oncol Rep. 2008 Jul;10(4):304-8.

Rash from EGFR inhibitors: opportunities and challenges for palliation.

Author information

1
Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. jatoi.aminah@mayo.edu.

Abstract

The epidermal growth factor receptor (EGFR) inhibitors represent a relatively new class of cancer agents that also provide new challenging side effects for cancer patients. This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment.

PMID:
18778556
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center